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Background: The choice of prosthesis for mitral valve replacement still remains controversial. This study assessed
mortality, bleeding events and reoperation in patients who underwent mitral valve replacement surgery with
biological or mechanical substitutes.
Methods: A total of 352 patients who underwent mitral valve replacement surgery between 1990 and 2008 with 5
to 23 years of follow-up were retrospectively evaluated in a cohort study.
Results: The 5, 10, 15 and 20 year survival rates after surgery using a mechanical substitute were 87.7%, 74.2%,
69.3% and 69.3%, respectively, while after surgery with a biological substitute, they were 87.6%, 71.0%, 64.2% and
56.6%, respectively. There was no significant difference between the two groups (p = 0.38). In the multivariate
analysis, the factors associated with death were age, bleeding events and renal failure. The probabilities of
remaining free of reoperation at 5, 10, 15 and 20 years after surgery using a mechanical substitute were 94.4%,
92.7%, 92.7% and 92.7%; after surgery with a bioprosthesis, they were 95.9%, 86.4%, 81.2% and 76.5%, respectively
(p = 0.073). There was a significantly higher incidence of reoperation for the bioprosthetic valve replacement group
(p = 0.008). The probabilities of remaining free of bleeding events at 5, 10, 15 and 20 years after surgery using a
mechanical substitute were 95.0%, 91.0%, 89.6% and 89.6%, respectively, while after surgery with a bioprosthesis,
they were 96.9%, 94.0%, 94.0% and 94.0%, (p = 0.267).
Conclusions: The authors concluded that: 1) mortality during follow-up was statistically similar for both groups; 2) there
was a greater tendency to reoperation in the bioprosthesis group; 3) the probability of remaining free from reoperation
remained unchanged after 10 years’ follow-up for patients with mechanical substitute valves; 4) the probability of
remaining fee from bleeding events remained unchanged after 10 years’ follow-up for patients given bioprostheses;
5) the baseline characteristics of patients were the greatest determinants of later mortality after surgery; 6) the type of
prosthesis was not an independent predictive factor of any of the outcomes tested in the multivariate analysis.
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Mitral valve replacement is a surgical procedure employed
when a valve is so severely compromised that preservation
is not viable, ruling out reparative surgery, and it is also
recommended for initial phase mitral insufficiency in
young patients, irrespective of symptoms, according to the
American Heart Association (ACC/AHA) [1].
As the longevity of populations steadily extends, the
high costs inherent to potential high complexity inter-
ventions merit due attention. In Brazil, life expectancy
increased by 11% between 1980 and 2000, according
to the Brazilian Institute of Geography and Statistics
(IGBE - Instituto Brasileiro de Geografia e Estatística)
and by 2050 there will be 226 elderly people over
60 years for every 100 children and adolescents [2]. It
has been shown that heart surgery can be effective in
patients in their seventies and eighties, but the cost of
operating these patients can be up to 35% higher [3].
Figures provided by DATASUS, the IT department of
the Brazilian National Health Service (SUS - Sistema
Único de Saúde) [4], show that implantation of pros-
thetic valves accounted for 16.4% of high complexity
cardiovascular surgery conducted in Brazil between
January 2008 and July 2013, with 40,506 operations to
implant valves, compared with 3,683 valvuloplasty op-
erations during the same period. Twenty-five percent of
Brazilian government spending on health services is
spent on cardiovascular care [5].
More than 30 years after the introduction of modern
prosthetic valves, the choice of whether to use a biological
or a mechanical valve in the mitral position is still the sub-
ject of debate [6,7]. This is because there is no ideal substi-
tute [8-11] that offers long-term durability, without the
need for oral anticoagulants, no increased risk of
thromboembolism and a functional mechanism similar
to the native mitral valve [10]. This decision becomes
an even greater challenge when patients have coexisting
conditions, such as advanced age, congestive heart fail-
ure, coronary artery disease, lung disease or renal failure.
The increase in life expectancy and in comorbidities
among patients needing valve replacement means that
choosing the most effective treatment (valvuloplasty,
mechanical prosthesis or bioprosthesis) demands consid-
eration of additional factors [12].
The objective of this study was to investigate mortality,
bleeding events and reoperation among patients who
underwent surgery for mitral valve replacement with a
biological or mechanical prosthesis in a tertiary hospital
that is a heart surgery referral center for the South of
Brazil.
Methods
The study design was a historical, observational cohort
study.Sample
Data were obtained from the archive service at the Hospital
de Clínicas de Porto Alegre (HCPA), Rio Grande do Sul,
Brazil, from the medical records of 846 inpatients over the
age of 18 who had undergone surgery in that hospital for
mitral valve replacement between 1 January 1990 and 31
December 2008 and had been followed-up for outcomes up
to June 2013. Cases with mitral valvuloplasty (n = 321) add-
itional heart surgery of other types (n = 109), previous heart
surgery (n = 60) and patients under the age of 18 (n = 4)
were all excluded, leaving a cohort of 352 patients (Figure 1).
The PEPI (Programs for Epidemiologists) version 4.0 soft-
ware package was used to calculate the sample size needed
to detect an effect size (difference between groups) with re-
lation to mortality of 15% between prosthesis types while
maintaining a statistical power of 80% and a 5% significance
level. The effect size was estimated from data published by
Hammermeister et al. [8,13,14]. With these parameters, the
minimum sample size was estimated at 314 cases.
The principal objective was to compare mortality be-
tween patients given mechanical or biological replacement
valves. Secondary objectives were: 1) to compare the prob-
ability of survival free from reoperation and bleeding
events across groups; and 2) to analyze predictors of death,
reoperation and bleeding events.
Clinical and surgical features of the cases were harvested
from information on patient records. The data thus col-
lected were evaluated by at least two authors independently.
The team's performance was subjected to quality control in
the form of double input data entry with crosschecking.
The study methodology was based on the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) [15].
Records of deaths were obtained from the Rio Grande do
Sul State Health Department healthcare information service
in Porto Alegre.
Complications related to prostheses were recorded in
accordance with the Guidelines for Reporting Mortality
and Morbidity After Cardiac Valve Interventions [16].
All operations were conducted under extracorporeal cir-
culation, with moderate hypothermia (32°) and cardiac ar-
rest, following the standardized technique adopted by the
Cardiovascular Surgery Department at the Hospital de
Clínicas de Porto Alegre, including anesthetic procedures.
All of the mechanical prostheses employed were bileaflet
valves and all of the biological prostheses implanted were
provided by the SUS. After surgery, all patients were trans-
ferred to the postoperative heart surgery ICU on mechanical
ventilation. Maximum duration of follow-up was 23 years,
with a mean of 9.2 ± 4.8 years and median of 8.9 years.
Ethical considerations
The research project was approved in advance by the
Medical Research Ethics Committee at the Hospital de
Figure 1 Flowchart of patients. This flowchart shows the inclusion and exclusion criteria of the studied subjects.
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0497, in order to obtain permission to conduct the
study in that hospital, with financial support from the
hospital’s research funding agency, the Fundo de Incen-
tivo à Pesquisa e Eventos (FIPE/HCPA).
Patient confidentiality and anonymity were guaranteed.
Use of the data collected for this study was restricted to
the objectives of this project.Definitions
The definitions listed below are all taken from the
Guidelines for Reporting Mortality and Morbidity After
Cardiac Valve Interventions [15].
The total number of deaths includes all deaths, from what-
ever causes, of patients who had had mitral valve surgery.
Early mortality is defined as all deaths within 30 days
of surgery, irrespective of the patient’s location.
Hospital mortality is any death after surgery while still
in hospital.
Valve-related mortality is defined as any death caused
by structural deterioration, nonstructural dysfunction,
thrombosis, embolism, bleeding events, endocarditis, or
death related to reoperation of a previously operated
valve. Deaths caused by heart failure in patients with ad-
vanced myocardial disease and no valve dysfunction are
not included in this category.
Cardiac deaths are all deaths resulting from cardiac
causes, including deaths related and unrelated to valves or
prostheses. This category includes deaths from congestiveheart failure, acute myocardial infarction and documented
arrhythmias, among others.
Sudden, unexplained and unexpected death are deaths
from unknown causes and their relationship with the
operated valve is also unknown. This item is a separate
category from valve-related mortality, to cover cases
when the cause cannot be determined from clinical or
necropsy findings.
Reoperation is when a previously operated valve is
repaired, altered, adjusted or replaced, according to the
Guidelines for Reporting Morbidity and Mortality after
Cardiac Valvular Interventions [16].
A bleeding event is defined as any episode of major in-
ternal or external bleeding that causes death, hospita-
lization, or permanent injury, such as a cerebral vascular
accident or loss of vision or bleeding requiring blood
transfusions.Statistical analysis
Quantitative variables were described using means and
standard deviations, where distribution was symmet-
rical, or medians and interquartile range, in cases of
asymmetrical distribution, and qualitative variables were
expressed as absolute and relative frequencies. Groups
were compared using Student’s t test for independent
samples (symmetrical distribution) or the Mann–Whitney
test (asymmetrical distribution) for quantitative variables,
and Pearson’s chi-square or Fisher’s exact test for qualita-
tive variables (rates and proportions).
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bleeding events were assessed using Kaplan-Meier curves.
The log-rank chi-square test was used to compare curves
across groups.
Cox's proportional risk model was employed to control
for confounding factors. Hazard ratios and 95% confidence
intervals were used to measure the effect. For all models,Table 1 Sample characterization
Variable Sample (n = 352) Mechan
Mean age ± SD 52.3 ± 13.4
Age group - n (%)
≤ 50 years 161 (45.7)
51 - 60 years 99 (28.1)
61 - 70 years 58 (16.5)
≥ 71 years 34 (9.7)
Gender - n (%)
Male 165 (46.9)
Female 187 (53.1)
BMI (Kg/m2) - Mean ± SD 24.4 ± 4.3
Obesity** - n (%) 33 (9.4)
Morbid obesity*** - n (%) 1 (0.3)
Functional class (NYHA) - n (%)
I-II 203 (57.7)
III-IV 149 (42.3)
Pathology – n (%)
Failure 155 (44.0)
Stenosis 83 (23.6)
DI with predominant stenosis 84 (23.9)
DI with predominant failure 30 (8.5)
Rhythm ECG – n (%)
Sinus 147 (42.0)
Atrial fibrillation 198 (56.6)
Others 5 (1.4)
Chronic atrial fibrillation - n (%) 169 (48.0)
Diabetes mellitus - n (%) 25 (7.1)
COPD - n (%) 56 (15.9)
Stroke - n (%) 24 (6.8)
SAH - n (%) 144 (40.9)
Creatinine > 2 mg/dl – n (%) 17 (4.8)
Dialysis - n (%) 3 (0.9)
Emergency surgery - n (%) 22 (6.3)
Endocarditis - n (%) 36 (10.2)
Rheumatic fever - n (%) 153 (43.5)
SD, standard deviation; BMI, body mass index; NYHA, New York Heart Association c
pulmonary disease; SAH, systemic arterial hypertension.
*Statistically significant association by the adjusted residuals test at 5% significance
**BMI ≥ 30 kg/m2; ***BMI ≥ 40 kg/m2.the criterion for a variable to be entered was a p value
below 0.20 on bivariate analysis, with the exception of type
of prostheses, which was included in all models since it
was the principal factor under study.
The significance level was set at 5% and data were ana-
lyzed using the program SPSS (Statistical Package for
the Social Sciences) version 17.0.ical valve (n = 247) Biological valve (n = 105) p
50.8 ± 12.5 55.8 ± 14.9 0.003
118 (47.8) 43 (41.0) < 0.001
77 (31.2)* 22 (21.0)
38 (15.4) 20 (19.0)
14 (5.7) 20 (19.0)*
116 (47.0) 49 (46.7) 1.000
131 (53.0) 56 (53.3)
24.8 ± 4.5 23.4 ± 3.8 0.003
27 (10.9) 6 (5.7) 0.181
1 (0.4) 0 (0.0) 1.000
143 (57.9) 60 (57.1) 0.990
104 (42.1) 45 (42.9)
0.719
104 (42.1) 51 (48.6)
61 (24.7) 22 (21.0)
60 (24.3) 24 (22.9)
22 (8.9) 8 (7.6)
114 (46.3)* 33 (31.7)
129 (52.4) 69 (66.3)* 0.039
3 (1.2) 2 (1.9)
112 (45.3) 57 (54.3) 0.156
18 (7.3) 7 (6.7) 1.000
39 (15.8) 17 (16.2) 1.000
17 (6.9) 7 (6.7) 1.000
105 (42.5) 39 (37.1) 0.413
9 (3.6) 8 (7.6) 0.187
1 (0.4) 2 (1.9) 0.213
10 (4.0) 12 (11.4) 0.017
22 (8.9) 14 (13.3) 0.288
112 (45.3) 41 (39.0) 0.331
lass; DI, double injury, ECG, electrocardiogram; COPD, chronic obstructive
.
Table 2 Surgery





Total surgical time (min) - mean ± SD 348 183.2 ± 61.2 175.5 ± 60.0* 202.5 ± 60.5 < 0.001
ECC time (min) - mean ± SD 352 76.5 ± 33.2 75.4 ± 34.7 79.2 ± 29.4 0.322
ECC > 120 min - n (%) 352 35 (9.9) 20 (8.1) 15 (14.3) 0.114
Ischemia time (min) - mean ± SD 350 57.6 ± 25.4 57.2 ± 24.7 58.4 ± 27.0** 0.691
SD, standard deviation; ECC, extracorporeal circulation; min, minutes.
*n = 243; **n = 103.
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As illustrated in Figure 1, 247 (70.2%) of the patients
were given mechanical prosthesis and 105 (29.8%) had a
bioprosthesis implanted (p ≤ 0.001).
Figure 1 lists the characteristics of the patients selected
for the study sample.
Patients who were fitted with mechanical prostheses
were younger, had higher body mass index and had a
higher proportion of sinus rhythm on electrocardiogram
(ECG) and of elective surgery than patients given bio-
logical replacement valves (P < 0.05). The remaining pre-
operative characteristics were similar across both groups
(Table 1).
The patients who underwent bioprosthesis implantation
experienced a significantly longer surgical time (<0.001)
(Table 2).
In-hospital outcomes broke down as follows: bioprosth-
esis patients spent longer in hospital (p < 0.001), spent lon-
ger on mechanical ventilation (p < 0.001) and spent longer
periods in the intensive care unit (ICU) (p = 0.009), when
compared with mechanical prosthesis patients, as shown
in Table 3. There were no statistically significant differ-
ences between groups for prolonged mechanical ventilation
(more than 5 days), acute myocardial infarction, cerebralTable 3 Postoperative outcomes
Variable Sample (n = 352) Mec
Hospitalization time (days) - median (P25–P75) 13 (10–20)
ICU time (days) - median (P25–P75) 3 (2.8–4)
PO hospitalization time (days) - median (P25–P75) 8 (7–11)
Mechanical ventilation time (h) - median (P25–P75) 15 (9–20)
Mechanical ventilation > 5 days - n (%) 7 (2.0)
AMI - n (%) 3 (0.9)
Stroke - n (%) 7 (2.0)
Arrhythmia requiring cardioversion - n (%) 13 (3.7)
Dialysis 2 (0.6)
Reoperation due to bleeding - n (%) 15 (4.3)
Cardiac tamponade - n (%) 10 (2.8)
Permanent TAVB 4 (1.1)
P25 = 25th Percentile; P75 = 75th Percentile; ICU, intensive care unit; PO, postoperatvascular accident, arrhythmia requiring cardioversion
or defibrillation, dialysis, reoperation due to bleeding,
cardiac tamponade or total, permanent atrioventricular block
(p > 0.05). Time on extracorporeal circulation and with the
aorta clamped were similar for both groups (p > 0.05).
Survival data
The long-term survival rates of the patients in this
study are illustrated in Figure 2. The 5, 10, 15 and
20 year survival rates after valve replacement surgery
by a mechanical substitute were 87.7% (CI: 83.6-91.8),
74.2% (CI: 67.3-81.1), 69.3% (CI: 61.3-77.3) and 69.3%
(CI: 61.3-77.3), respectively. For the patients who re-
ceived a biological substitute, the survival rates were
87.6% (CI: 81.3-93.9), 71.0% (CI: 62.0-80.0), 64.2% (CI: 54.6-
73.8) and 56.6% (CI: 45.0-68.2), respectively. Thus, there
was no significant difference in the survival of the pa-
tients between the two groups (p = 0.386) throughout
the follow-up period.
The multivariate Cox regression analysis demon-
strated no association between the type of valve and
death (p = 0.855), as shown in Table 4. The factors
statistically associated with the death outcome were
age over 60 years (61–70: Harzard ratio [HR] = 1.98;hanical prosthesis (n = 247) Biological prosthesis (n = 105) p
12 (9–18) 17 (13–27) < 0.001
3 (2.8–3.8) 3.3 (2.9–4.2) 0.009
8 (7–10) 10 (8–14) < 0.001
14 (8–20) 17 (12–24) < 0.001
4 (1.6) 3 (2.9) 0.431
2 (0.8) 1 (1.0) 1.000
5 (2.0) 2 (1.9) 1.000
7 (2.8) 6 (5.7) 0.219
0 (0.0) 2 (1.9) 0.088
10 (4.0) 5 (4.8) 0.776
7 (2.8) 3 (2.9) 1.000
2 (0.8) 2 (1.9) 0.586
ive; AMI, acute myocardial infarction; TAVB, total atrioventricular block.
Figure 2 Cumulative probability to survival based on the type of valve prosthesis. Kaplan-Meier curve to assess the cumulative probability
to survival based on the type on the valve prosthesis.
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HR = 2.96; 95% CI: 1.54–5.71), renal failure (HR =
4.41; 95% CI: 2.36–8.25) and bleeding events (HR =
3.13; 95% CI: 1.68–5.80).
As the groups differed significantly for age, body mass
index (BMI, Kg/m2), electrocardiogram (ECG) rhythm
and emergency surgery, a propensity score was added to
the model to minimize confounding biases into the study.
Even after adjusting for propensity score, there was no
modification of the results obtained by Cox regression.
The risk of death for mechanical prosthesis was very simi-
lar when adjusted for propensity score, with HR = 0.97
(95% CI: 0.62-1.53, p = 0.93).
A significantly higher incidence of reoperation for valve
replacement (p = 0.008) and death (p = 0.003) was found
in patients who underwent biological valve replacement
(Table 5).
There was no significant difference between the groups
regarding the cause of death (p = 1.000). The most frequent
cause was non-cardiac (39.6%), followed by prosthesis-
related causes (35.2%), as shown in Table 6.
Figure 3 illustrates the probability of long-term sur-
vival free from reoperation for the study patients. The
probabilities of survival free from reoperation at 5, 10,
15 and 20 years after surgery for valve replacement with
a mechanical prosthesis were 94.4% (CI: 91.5-97.3), 92.7%(CI: 89.2-96.2), 92.7% (CI: 89.2-96.2) and 92.7% (CI: 89.2-
96.2) respectively and the figures for biological valves
were 95.9% (CI: 92.0-99.8), 86.4% (CI: 79.1-93.7), 81.2%
(CI: 72.4-90.0) and 76.5% (CI: 66.1-86.9) respectively. Pa-
tients with biological replacement valves tended to have a
greater probability of reoperation, particularly after the
first 10 years’ follow-up (p = 0.073).
As shown in Table 7, after adjustment by Cox
multivariate regression, type of valve continued not
to exhibit any association with reoperation (p = 0.075).
Factors that did remain statistically associated with
reoperation after multivariate analysis were male sex
(HR = 2.50; 95% CI: 1.20-5.35), diameter of prosthesis
(HR = 0.82; 95% CI: 0.69-0.97); and endocarditis (HR =
2.44; 95% CI: 1.04-5.70).
After adjustment by propensity score, the use of bio-
logical prostheses showed an HR = 1.68 (95% CI: 0.82-
3.45, p = 0.155), and did not modify the results obtained
by Cox regression.
Figure 4 illustrates the probability of long-term sur-
vival free from bleeding events, by type of prosthesis.
The probabilities of survival free from bleeding events at
5, 10, 15 and 20 years after surgery for valve replacement
with a mechanical prosthesis were 95.0% (CI: 92.3-97.7),
91.0% (CI: 86.5-95.5), 89.6% (CI: 84.5-94.7) and 89.6%
(CI: 84.5-94.7) respectively and for patients with
Table 5 Outcomes in the cohort during the follow-up period
Variable Sample
(n = 352) n (%)
M
Reoperation for valve replacement 33 (9.4)
Bleeding events 23 (6.5)
Thromboembolic events 7 (2.0)
Total number of deaths 91 (25.9)




ICU, intensive care unit; *none exceeded the perioperative period; **deaths after 30
A significantly higher incidence of reoperation for valve replacement (p = 0.008) and
replacement (Table 5).
Table 4 Predictors of death by Cox regression analysis
Variable HR (95% CI) p
Mechanical prosthesis 0.96 (0.61-1.50) 0.855
Renal failure 4.41 (2.36-8.25) < 0.001
Bleeding events 3.13 (1.68-5.80) < 0.001
Age group
≤ 50 years 1.0
51–60 years 1.39 (0.82-2.38) 0.224
61–70 years 1.98 (1.11-3.56) 0.022
≥ 71 years 2.96 (1.54-5.71) 0.001
Mitral regurgitation 1.49 (0.97-2.29) 0.069
SAH 1.45 (0.95-2.23) 0.088
Chronic atrial fibrillation 1.46 (0.91-2.33) 0.114
Emergency surgery 1.69 (0.82-3.47) 0.153
Diabetes mellitus 1.62 (0.82-3.19) 0.163
Ischemia time 1.01 (0.99-1.01) 0.180
ICU time (h) 1.00 (0.99-1.00) 0.492
Hospitalization time 1.01 (0.99-1.02) 0.501
MV time (h) 1.00 (1.00-1.01) 0.589
Diameter 1.03 (0.92-1.15) 0.654
CHF class III and IV 1.10 (0.70-1.75) 0.675
Postoperative stroke 1.36 (0.31-5.99) 0.681
COPD 0.91 (0.48-1.70) 0.759
ECC time > 120 min 1.11 (0.40-3.10) 0.843
Rheumatic fever 1.02 (0.60-1.71) 0.949
HR, hazard ratio; 95% CI = 95% confidence interval; BMI, body mass index;
ECC, extracorporeal circulation; ICU, intensive care unit; MV, mechanical
ventilation; CHF, congestive heart failure; AMI, acute myocardial infarction;
COPD, chronic obstructive pulmonary disease; SAH, systemic
arterial hypertension.
Significant results (p < 0.005) are highlighted in bold.
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100), 94.0% (CI: 88.7-99.3), 94.0% (CI: 88.7-99.3) and 94.0
(CI: 88.7-99.3) respectively. There was no statistically sig-
nificant difference between the 2 groups (p = 0.267).
As shown in Table 8, after adjustment by Cox multi-
variate regression, type of valve continued not to ex-
hibit any association with the incidence of bleeding
events (p = 0.213). Factors that did remain statistically
associated with occurrence of bleeding events after
multivariate analysis were body mass index ≥ 30 kg/m2
(HR = 4.41; 95% CI: 1.66-11.8), chronic obstructive pul-
monary disease (HR = 2.87; 95% CI: 1.19-6.91), more than
5 days on mechanical ventilation in the ICU (HR = 5.34;
95% CI: 1.13-25.4) and mitral insufficiency (HR = 2.56;
95% CI: 1.05-6.25).
Considering the presence of bleeding events stratified
by age groups, no significant difference were found be-
tween groups in years: <60, 60–65, 65–70, 70–75, 75–
80, and >80, with p = 0.895, being <60 = 6%, 60-65 =
8.3%, 65-70 = 10.3%, 70-75 = 7.7%, 75-80 = 0.0, >80 = 0.
When adjusted for propensity score, no significant
change was obtained in the values of the risk measure
HR = 2.3 (95% CI: 0.76-5.96, p = 0.149).
Discussion
Mortality
The actuarial mortality rate observed in this cohort was
25.9%, and there was no difference between the groups
that received the mechanical and biological prostheses
throughout the follow-up time (p = 0.386) (Figure 2). This
result may have occurred due to the increased risk related
to anticoagulation in patients who received the mechan-
ical prostheses being partially offset by the increased risk
of reoperation in patients who received the biological
prostheses.
Hammermeister et al. [8,13,14] observed even higher
numbers of deaths in a prospective randomized clinical
trial comparing porcine prostheses with mechanicalof up to 23 years
echanical prosthesis
(n = 247) n (%)
Biological prosthesis
(n = 105) n (%)
p
16 (6.5) 17 (16.2) 0.008
18 (7.3) 5 (4.8) 0.521
5 (2.0) 2 (1.9) 1.000
52 (21.1) 39 (37.1) 0.003
10 (4.0) 11 (10.5) 0.037
4 (1.6) 5 (4.8) 0.133
5 (2.0) 6 (5.7) 0.092
42 (17.0) 28 (26.7) 0.053
days of hospitalization.
death (p = 0.003) was found in patients who underwent biological valve
Table 6 Causes of death





(n = 52) n (%)
Biological
prosthesis
(n = 39) n (%)
p
Prosthesis-related 32 (35.2) 18 (34.6) 14 (35.9) 1.000
Others 59 (64.8) 34 (65.4) 25 (64.1) 1.000
Cardiac 21 (23.1) 12 (23.1) 9 (23.1) 1.000
Non-cardiac 36 (39.6) 21 (40.4) 15 (38.5) 1.000
Sudden or
unexplained
2 (2.2) 1 (1.9) 1 (2.6) 1.000
*Deaths represent 25.9% (n = 91) of the samples.
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placement over an 18 year follow-up period, reporting
total mortality of 30%, with 22% related to mechanical
prostheses and 16% related to bioprostheses. Five year sur-
vival was 58 ± 6% and 70 ± 5% for patients with mechan-
ical and biological prostheses respectively. The elevated
number of deaths was probably the result of the fact that
these implants were fitted between 1970 and 1980. Many of
the deaths of bioprostheses patients happened more
than 10 years after surgery and can be attributed to pri-
mary prosthesis dysfunction, with or without reinterven-
tion. The authors concluded that survival rates were
similar for bioprostheses and mechanical prosthesis pa-
tients over a mean of eight years.Figure 3 Cumulative probability of reoperation. Kaplan-Meier curve to
the type of valve prosthesis.Our findings are also in agreement with survival results
of a randomized clinical trial conducted in Edinburgh by
Oxeham and colleagues [17], who compared the outcomes
of 261 patients who had had mitral valves replaced with
either a mechanical (n = 129) or porcine prosthesis be-
tween 1975 and 1979 with a 20-year follow-up period.
They found that there was an advantage in terms of
survival from 10 years onwards for mechanical pros-
thesis patients, but that this advantage disappeared by
20 years' follow-up (p < 0.0001). In a similar vein to this
study, these authors found that survival rates at 10 and
20 years after valve replacement surgery to fit a mechan-
ical prostheses were 52.7% and 22.4% while for biological
prostheses they were 46.5% and 18.4% respectively, which
did not attain statistical significance (p = 0.41).
Advanced age has also been identified as a predictive
factor in other cohorts that have been studied, including
a prospective multicenter cohort study conducted from
January to December of 2001 at eight hospitals in the
north of the United States. They reviewed 3150 cases of
mitral valve surgery including 1688 patients, with a
mean age of 66.7, who were given replacement valves
(53.6%), observing 12% mortality [18]. In addition to
age, a further nine variables were also associated with
death after mitral surgery: female sex, diabetes, coron-
ary disease, prior cerebral vascular accident, elevatedassess the cumulative probability of reoperation-free time according to
Table 7 Predictors of reoperation by Cox regression
analysis
Variable HR (95% CI) p
Biological prosthesis 1.89 (0.94-3.82) 0.075
Male gender 2.54 (1.20-5.35) 0.015
Valve prosthesis diameter 0.82 (0.69-0.97) 0.019
Endocarditis 2.44 (1.04-5.70) 0.040
Arrhythmia 2.92 (0.86-9.89) 0.085
Emergency surgery 1.98 (0.71-5.56) 0.192
RF 1.12 (0.24-5.29) 0.885
HR: hazard ratio; 95% CI = 95% confidence interval; RF = renal failure.
Significant results (p < 0.005) are highlighted in bold.
Ribeiro et al. BMC Cardiovascular Disorders 2014, 14:146 Page 9 of 12
http://www.biomedcentral.com/1471-2261/14/146creatinine (≥1.3 mg/dl), New York Heart Association
(NYHA) class IV, heart failure, valve replacement ra-
ther than valvuloplasty and emergency surgery.
Likewise, Ruel et al. [19] compared mortality rates for
214 patients younger than 60 years who had surgery for
mitral valve replacement with mechanical or biological
substitutes between 1969 and 2004, with up to a 35 year
postoperative follow-up period (mean survival 24 ±
3.1 years). There was no difference in survival between
groups, with rates of 51.4 ± 4.4% and 33.8 ± 5.3% for 20
and 25 years respectively after bioprosthesis implantationFigure 4 Cumulative time free of bleeding events. Kaplan-Meier curve
the type of valve prosthesis.and 43.2 ± 5.7% and 40.8 ± 5.9% respectively for mechan-
ical valves. Age group, as observed in this study, was also
predictor factor for death.
In a 20-year follow-up cohort study, Khan et al. [20]
compared outcomes for 513 patients with mechanical
mitral prostheses with 402 given bioprostheses. Mechan-
ical prostheses were preferred for younger patients (p =
0.0001). The same study found no significant difference
in survival between prosthesis groups using multivariate
analysis. Advanced age was once more a predictor of
mortality, as in the cohort described here.
Jamieson et al. [21] found that freedom from prosthesis-
related mortality rates were only better than rates for bio-
logical replacements in the age group from 51 to 60, with
75.4 ± 8.3% survival for bioprostheses and 87.5 ± 8.7% for
mechanical valves, while for patients over 70 rates were
similar. The predictors factors for mortality were age, male
sex, bioprosthesis, diameter of prosthesis and concurrent
revascularization surgery. In the present study, type of
prosthesis was not a significant predictor factor of death,
with p = 0.461.
After multivariate analysis, Kim and colleagues [22]
also identified age group as an independent risk factor
for death, echoing Kulik et al. [23], Khan et al. [20],
Yau et al. [24] and Jamienson et al. [25]. Some studies
attempted to perform risk stratification in heart surgery;to assess the cumulative of time free of bleeding events according to
Table 8 Predictors of bleeding events by Cox regression
analysis
Variable HR (95% CI) P
Mechanical prosthesis 1.90 (0.69–5.18) 0.213
BMI ≥ 30 kg/m2 4.41 (1.66–11.8) 0.003
COPD 2.87 (1.19–6.91) 0.019
MV > 5 days 5.34 (1.13–25.4) 0.035
Mitral regurgitation 2.56 (1.05–6.25) 0.040
SAH 2.31 (0.96–5.56) 0.062
Ischemia time 1.01 (0.99–1.02) 0.131
Diabetes mellitus 1.74 (0.48–6.36) 0.404
Hospitalization time 1.01 (0.98–1.03) 0.740
Rheumatic fever 1.15 (0.41–3.27) 0.790
RF 1.28 (0.14–11.4) 0.828
HR: hazard ratio; 95% CI = 95% confidence interval; BMI = body mass index;
SAH = systemic arterial hypertension; COPD = chronic obstructive pulmonary
disease; MV =mechanical ventilation; RF = renal failure.
Significant results (p<0.005) are highlighted in bold.
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cation [25-27], such as pulmonary hypertension, functional
class, emergency surgery, type of prosthesis, atrial fibrilla-
tion, multiple surgeries, renal failure, peripheral vascular
disease, non-rheumatic diseases, small body surface and
prosthesis-patient mismatch.
Bleeding events
In the sample described here, 6.5% of cases involved
major bleeding events (n = 23) and the majority of these
were associated with mechanical prostheses (p = 0.521),
with a statistically significant difference. This may be
due to the low number of events, to well-controlled
anticoagulation of patients given mechanical replace-
ment valves or to anticoagulation prescribed for other
indications over the course of the follow-up period.
Some studies associated mechanical prostheses with
bleeding events, as an independent risk factor, due to
the need for anticoagulation. The study conducted by
Khan and colleagues [20] reported a 2.1% bleeding event
rate for patients with mitral mechanical prostheses,
compared with 1.1% for bioprostheses, with a fre-
quency of occurrence over 15 years that was similar
for both groups (86% for bioprostheses and 85% for
mechanical valves), as observed in the present cohort.
Kulik et al. [23] observed differences in their cohort in
terms of bleeding events and found that fitting a
mechanical prosthesis was an independent factor for
bleeding events (p = 0.02), which was not observed in
this study.
In the present sample, 4.8% of the patients presented
with renal failure. In a cohort of dialysis patients, Umezu
et al. [27] identified bleeding events in 29.7% of the cases,
which was a much higher percentage than those found inthe current sample. The authors also observed a higher in-
cidence of bleeding events in patients with mechanical
valve replacements compared with biological valve re-
placements, which was not seen in the present cohort.
Reoperation
Most of the publications available in the literature dem-
onstrated that the risk of reoperation begins to increase
10 years after valve replacement surgery, most likely due
to prosthesis dysfunction. This risk increases progressively
over time and decreases with increasing age [17,19]. In the
present study, a trend towards reoperation was observed
after 10 years of follow-up (p = 0.073).
The factors related to reoperation found in the
current study were male gender, prosthesis diameter
and endocarditis.
In a randomized trial by Oxeham (Edinburgh Trial)
[2], reoperation was more frequent in the group of pa-
tients who underwent bioprosthesis implantation com-
pared to mechanical prosthesis implantation (p < 0.001).
In a clinical trial by Hammermeister et al. [13,14], there
was no significant difference in the probability of reoper-
ation between the two types of prostheses (p = 0.23). In
addition, in a review study, Rahimtoola [9] concluded
that the major disadvantage of using a bioprosthesis is
the higher incidence of reoperation, which can result in
a higher mortality rate.
Endocarditis was also a predictor for reoperation in a
study by Yau et al. [24], with HR = 8.93; 95% CI: 1.16–
68.7; p = 0.04.
The 1062-patient cohort followed by Ruel et al. [26]
had rates of survival free from reoperation after replace-
ment with mechanical valves of 96.4%, 94.8% and 94.2%
for 10, 15 and 20 years after surgery, respectively, similar
to the data from the present cohort. For bioprostheses,
survival free from reoperation rates were 79.8%, 63.3%
and 57.6% (p < 0.001). Advanced age was a protective
factor against reoperation due to structural mitral bio-
prosthesis dysfunction (HR = 0.98; p ≤ 0.001), which can
be attributed to reduced deterioration of the prosthesis
in older patients.
Jamieson et al. [21] assessed over a 15 year period the
performance of 959 biological valve prostheses im-
planted in 943 patients and 961 mechanical prostheses
implanted in 839 patients in the mitral position. The re-
operation rate per year for mechanical prostheses was
0.5 events per 100 patients, and for biological pros-
theses, it was 3.7 events per 100 patients. The predictors
for reoperation were age (n = 240, mean 56.0 ± 12.9 years,
HR = 0.98, 95% CI 0.97–0.99) and the type of prosthesis,
where a frequency of 2.7% was found for mechanical
valves (n = 26) and a frequency of 22.2% was found for
bioprostheses (n = 214, p = 0.001, HR = 0.19; 95% CI:
0.13–0.29, p < 0.001).
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et al. [20], Jamienson and cols [21], as in this present
study, in the first five years was the higher incidence
from free of deaths, valve-related reoperation and
bleeding.Study limitations
This is a retrospective and observational study, and it is
subject to bias and confounding factors that cannot be
measured. In addition, it was conducted in a single cen-
ter and exhibited an insufficient sample size for identify-
ing rare events.Conclusions
The choice of replacement valve type remains a decision
that should be taken by physician and patient in conjunc-
tion and must be individualized, taking into consideration
the risks of reoperation and of chronic anticoagulation
and their consequences, plus the comorbidities, life ex-
pectancy and characteristics of the patient and their life-
style, in order to increase life expectancy and quality of
life. Studies with long-term follow-up that can help in this
choice are therefore relevant.
Although the incidence of death and reoperation
were significantly higher in patients who underwent
valve replacement with a biological substitute, the
findings in this cohort demonstrated that the type of
prosthesis was not an independent predictor associ-
ated with any of the clinical outcomes assessed, death,
bleeding events and reoperation, using multivariate
regression analysis. The mortality data obtained in
this study were in agreement with the current litera-
ture, with 5, 10, 15 and 20 year survival rates similar
in the two groups. Some of the results found in this
study, such as the predictors found in the multivariate
analysis, were also reported in the literature, while
others need to be further studied to clarify their importance.
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